AR044561A1 - Derivados de estatina - Google Patents
Derivados de estatinaInfo
- Publication number
- AR044561A1 AR044561A1 ARP040101813A ARP040101813A AR044561A1 AR 044561 A1 AR044561 A1 AR 044561A1 AR P040101813 A ARP040101813 A AR P040101813A AR P040101813 A ARP040101813 A AR P040101813A AR 044561 A1 AR044561 A1 AR 044561A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- group
- ono2
- integer
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 8
- 229910004679 ONO2 Inorganic materials 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003031 C5-C7 cycloalkylene group Chemical group 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 150000002828 nitro derivatives Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Nitroderivados de estatina que tienen actividad farmacológica mejorada y mayor tolerabilidad. Se pueden emplear para tratar y/o prevenir diversas enfermedades, en particular síndromes coronarios, afecciones neurodegenerativas como también para reducir los niveles de colesterol. Reivindicación 1: Un compuesto caracterizado porque tiene fórmula general (1) o una sal aceptable para uso farmacéutico o estereoisómero del mismo, donde: X es -O-, -S-, -NH- o -NHR1-, siendo R1 alquilo lineal o ramificado C1-10, preferentemente CH3; R es un residuo estatina seleccionado del grupo de fórmulas (2); Y es un radical bivalente que tiene el siguiente significado: a) C1-20 alquileno lineal o ramificado, preferentemente C1-10, sustituyéndose opcionalmente con uno o más de los sustituyentes seleccionados entre el grupo que consiste en: átomos de halógeno, hidroxi, -ONO2 o T0, donde T0 es -OC(O)(C1-10 alquilo)-ONO2 o -O(C1-10 alquilo)-ONO2; cicloalquileno C5-7 en el anillo cicloalquileno, siendo el anillo eventualmente sustituido con cadenas laterales T, donde T es alquilo lineal o ramificado C1-10, preferentemente CH3; b) un compuesto de fórmula (3); c) un compuesto de fórmula (4), donde n es un número entero ente 0 y 20, y n1 es un número entero de 1 a 20; d) un compuesto de fórmula (5), donde: n1 tiene los valores que se han definido y n2 es un número entero entre 0 y 2; X1 = -OCO- o -COO- y R2 es H o CH3; e) un compuesto de fórmula (6), donde: n1, n2, R2 y X1 tienen los valores que se han definido; Y1 es -CH2-CH2- o -CH=CH-(CH2)n2-; f) un compuesto de fórmula (7), donde: n1 y R2 tienen los valores que se han definido, R3 es H o COCH3; con la condición de que cuando Y se selecciona entre radicales bivalentes mencionados bajo b)-f), el grupo -ONO2 se une a -(CH2)n1; g) un compuesto seleccionado del grupo de fórmulas (8), donde X2 es -O- o -S-, n3 es un número entero de 1 a 6, preferentemente de 1 a 4, R2 tiene los valores que se han definido; h) un compuesto de fórmula (9), donde: n4 es un número entre 0 y 10; n5 es un número entero de 1 a 10; R4, R5 R6, R7 son iguales o diferentes, y son H o C1-4-alquilo lineal o ramificado, preferentemente R4, R5, R6, R7 son H; donde el grupo -ONO2 se une al resto de fórmula (10), donde n5 tiene los valores que se han definido; Y2 es un anillo heterocíclico de 5 ó 6 miembros saturado, insaturado o aromático, que tiene uno o más heteroátomos seleccionados entre nitrógeno, oxígeno, azufre, y seleccionados por ejemplo entre un resto del grupo de fórmulas (11).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03101530 | 2003-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044561A1 true AR044561A1 (es) | 2005-09-21 |
Family
ID=33483985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101813A AR044561A1 (es) | 2003-05-27 | 2004-05-26 | Derivados de estatina |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US7166638B2 (es) |
| EP (1) | EP1626716B1 (es) |
| KR (1) | KR101136434B1 (es) |
| CN (1) | CN1794987B (es) |
| AR (1) | AR044561A1 (es) |
| AT (1) | ATE353214T1 (es) |
| AU (1) | AU2004243443B2 (es) |
| BR (1) | BRPI0410049A (es) |
| CA (1) | CA2527168C (es) |
| CY (1) | CY1107614T1 (es) |
| DE (1) | DE602004004652T2 (es) |
| DK (1) | DK1626716T3 (es) |
| ES (1) | ES2280978T3 (es) |
| MX (1) | MXPA05012755A (es) |
| NO (1) | NO20056152L (es) |
| NZ (1) | NZ543086A (es) |
| PL (1) | PL379019A1 (es) |
| PT (1) | PT1626716E (es) |
| RU (1) | RU2362770C2 (es) |
| SI (1) | SI1626716T1 (es) |
| WO (1) | WO2004105754A1 (es) |
| ZA (1) | ZA200509460B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5198063B2 (ja) | 2004-08-26 | 2013-05-15 | アッパラオ・サティアム | 新規バイオ開裂性リンカー |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| AU2007211508B2 (en) | 2006-02-03 | 2012-08-23 | Nicox Science Ireland | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies |
| EP1889617A1 (en) * | 2006-07-11 | 2008-02-20 | Freie Universität Berlin | Triphenyl modified 5-membered heterocycles and their use as anticancer and antiflammatory agents |
| US20100152274A1 (en) * | 2007-04-13 | 2010-06-17 | Nicox S.A. | Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester |
| JP2010531299A (ja) * | 2007-06-25 | 2010-09-24 | ニコックス エス エイ | 肺動脈高血圧症の治療における一酸化窒素放出性スタチンの使用 |
| US20090226515A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Statin compositions |
| WO2009147009A2 (en) * | 2008-06-06 | 2009-12-10 | Nicox S.A. | Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug |
| US7807716B2 (en) * | 2008-09-24 | 2010-10-05 | Oral Delivery Technology Ltd. | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use |
| CN101613284B (zh) * | 2009-06-26 | 2013-05-08 | 四川抗菌素工业研究所有限公司 | 洛伐他汀、辛伐他汀和辛伐他汀-6-氧化物的硝基氧基衍生物及其制备方法 |
| EP2371404A3 (de) | 2010-03-30 | 2014-08-20 | Biotronik AG | Medizinisches Implantat mit einer Beschichtung bestehend aus oder enthaltend mindestens einen Nitro-Statin-Wirkstoff |
| WO2011160974A2 (en) | 2010-06-21 | 2011-12-29 | Nicox S.A. | Statin derivatives |
| US9844599B2 (en) | 2013-01-21 | 2017-12-19 | Apparao Satyam | Nitric oxide releasing produgs of therapeutic agents |
| WO2014168933A1 (en) | 2013-04-08 | 2014-10-16 | Cytodyn Inc. | Felinized antibodies and methods of treating retroviral infections in felines |
| EP2949324A1 (en) | 2014-05-27 | 2015-12-02 | Consorci Institut Catala de Ciencies Cardiovasculars | Prevention and/or treatment of ischemia/reperfusion injury |
| CN104327057B (zh) * | 2014-10-17 | 2017-01-18 | 上海应用技术学院 | 多取代吲哚类他汀内酯脱水化合物及其用途 |
| CN108349911B (zh) * | 2015-09-07 | 2022-05-13 | 浙江华海药业股份有限公司 | 可释放一氧化氮的前药分子 |
| CN108114282B (zh) * | 2016-11-28 | 2021-03-02 | 北京大学第三医院 | 他汀类化合物治疗缺血性疾病的用途 |
| ES2877646T3 (es) | 2017-03-31 | 2021-11-17 | Fundacio Inst De Recerca De Lhospital De La Santa Creu I Sant Pau | Estatina para la prevención o reducción de los daños relacionados con la isquemia |
| CN107098843B (zh) * | 2017-03-31 | 2020-04-28 | 中国医药集团总公司四川抗菌素工业研究所 | 一种fk409类no供体型他汀降血脂药物衍生物及其制备方法 |
| CN107043373B (zh) * | 2017-03-31 | 2020-04-28 | 中国医药集团总公司四川抗菌素工业研究所 | 一种噁三唑类no供体型他汀衍生物及其制备方法和应用 |
| EP3381452A1 (en) | 2017-03-31 | 2018-10-03 | Instituto Catalán de Ciencias Cardiovasculares (ICCC), Hospital de la Santa Creu i Sant Pau, Avda. | Statin for prevention/reduction of ischemia-related damage |
| CN106938979B (zh) * | 2017-03-31 | 2019-08-02 | 中国医药集团总公司四川抗菌素工业研究所 | 一种no供体型他汀衍生物、制备方法和应用 |
| CN110183329B (zh) * | 2019-06-19 | 2022-09-13 | 中国医药集团总公司四川抗菌素工业研究所 | 硝酸酯类no供体型他汀衍生物及其制备方法 |
| CN113929609B (zh) * | 2021-10-13 | 2024-08-23 | 深圳弘汇生物医药有限公司 | 一种调血脂的阿托伐他汀衍生物及其组合物、制备方法和医药用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8927981D0 (en) * | 1989-12-11 | 1990-02-14 | Ici Plc | Carbamoyl derivative |
| IE904261A1 (en) * | 1990-11-26 | 1992-06-03 | Sanofi Sa | Use of a statin derivative in the treatment of eye¹complaints |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| AU7440796A (en) * | 1995-10-13 | 1997-04-30 | United States Of America, As Represented By The Secretary Of Agriculture, The | In ovo yeast treatment to diminish salmonellae populations in poultry |
| IT1276071B1 (it) | 1995-10-31 | 1997-10-24 | Nicox Ltd | Compositi ad attivita' anti-infiammatoria |
| IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1311923B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| IT1311924B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
| US6573385B1 (en) * | 1999-11-11 | 2003-06-03 | Biocon India Limited | Process for manufacturing simvastatin and novel intermediates thereof |
| US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
| US20030100493A1 (en) | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
-
2004
- 2004-05-20 US US10/849,561 patent/US7166638B2/en not_active Expired - Fee Related
- 2004-05-24 CN CN2004800144981A patent/CN1794987B/zh not_active Expired - Fee Related
- 2004-05-24 AT AT04741636T patent/ATE353214T1/de active
- 2004-05-24 DK DK04741636T patent/DK1626716T3/da active
- 2004-05-24 CA CA2527168A patent/CA2527168C/en not_active Expired - Fee Related
- 2004-05-24 BR BRPI0410049-2A patent/BRPI0410049A/pt not_active IP Right Cessation
- 2004-05-24 NZ NZ543086A patent/NZ543086A/en not_active IP Right Cessation
- 2004-05-24 SI SI200430242T patent/SI1626716T1/sl unknown
- 2004-05-24 KR KR1020057022246A patent/KR101136434B1/ko not_active Expired - Fee Related
- 2004-05-24 ES ES04741636T patent/ES2280978T3/es not_active Expired - Lifetime
- 2004-05-24 PT PT04741636T patent/PT1626716E/pt unknown
- 2004-05-24 RU RU2005138139/04A patent/RU2362770C2/ru not_active IP Right Cessation
- 2004-05-24 AU AU2004243443A patent/AU2004243443B2/en not_active Ceased
- 2004-05-24 EP EP04741636A patent/EP1626716B1/en not_active Expired - Lifetime
- 2004-05-24 PL PL379019A patent/PL379019A1/pl not_active Application Discontinuation
- 2004-05-24 DE DE602004004652T patent/DE602004004652T2/de not_active Expired - Lifetime
- 2004-05-24 WO PCT/EP2004/050897 patent/WO2004105754A1/en not_active Ceased
- 2004-05-24 MX MXPA05012755A patent/MXPA05012755A/es active IP Right Grant
- 2004-05-26 AR ARP040101813A patent/AR044561A1/es not_active Application Discontinuation
-
2005
- 2005-11-22 ZA ZA200509460A patent/ZA200509460B/en unknown
- 2005-12-23 NO NO20056152A patent/NO20056152L/no not_active Application Discontinuation
-
2006
- 2006-11-01 US US11/590,770 patent/US7297808B2/en not_active Expired - Fee Related
-
2007
- 2007-04-13 CY CY20071100515T patent/CY1107614T1/el unknown
- 2007-10-05 US US11/905,910 patent/US7563909B2/en not_active Expired - Fee Related
- 2007-10-05 US US11/905,893 patent/US7462716B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044561A1 (es) | Derivados de estatina | |
| AR045145A1 (es) | Nitro-oxi derivados bloqueadores del receptor de angiotensina ii | |
| AR047081A1 (es) | Derivados de prostaglandinas, metodos para su preparacion, composiciones farmaceuticas que las contienen y su uso en el tratamiento del glaucoma y de la hipertension ocular. | |
| PE20220134A1 (es) | Compuestos de pirrolidina | |
| PE20080093A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| CO6220840A2 (es) | Formulaciones para el tratamiento de cancer | |
| PE20110547A1 (es) | Compuestos de isoindolina con actividad anticancerigena | |
| PA8783401A1 (es) | Derivados de piperidina/piperazina | |
| EA200200938A1 (ru) | Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение | |
| AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
| AR054881A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, un proceso para su preparacion, una composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento para el tratamiento de la hepatitis c | |
| ES2188194T3 (es) | 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4. | |
| AR057082A1 (es) | Derivados de ciclohexilaminisoquinolona | |
| AR058569A1 (es) | Inhibidores de histona desacetilasa para mejorar la actividad de agentes antifungicos | |
| AR054475A1 (es) | Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion | |
| CO6150149A2 (es) | Compuestos azabiciclicos como inhibidfores de la recaptacion de monoaminas | |
| MX2011011281A (es) | Compuesto de carbinol que tiene un enlazante heterociclico. | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
| PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
| AR035727A1 (es) | Compuestos macrolido-esteroides o macrolido no-esteroide, sus sales y solvatos, su uso y procedimiento para su preparacion | |
| AR060427A1 (es) | Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares | |
| AR061598A1 (es) | Nitroderivados heterociclicos como antagonistas de receptor de endotelina | |
| AR056868A1 (es) | Nitrooxi derivados de esteroides, composiciones farmaceuticas y su uso para tratar trastornos de la piel o de la membrana mucosa | |
| CY1109371T1 (el) | Παραγωγα σουλφαμικου βενζοθειοφαινιου ως αναστολεις σουλφατασης στεροειδους | |
| AR057414A1 (es) | Derivados de prostaglandina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |